Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00856908
First received: March 5, 2009
Last updated: November 27, 2012
Last verified: November 2012
Results First Received: July 24, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Subject);   Primary Purpose: Treatment
Condition: Type II Diabetes
Interventions: Drug: AZD1656
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Experimental AZD1656 dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
Placebo Comparator placebo Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days

Participant Flow:   Overall Study
    Experimental     Placebo Comparator  
STARTED     15     5  
COMPLETED     14     5  
NOT COMPLETED     1     0  
Lost to Follow-up                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Experimental AZD1656 dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
Placebo Comparator placebo Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
Total Total of all reporting groups

Baseline Measures
    Experimental     Placebo Comparator     Total  
Number of Participants  
[units: participants]
  15     5     20  
Age  
[units: years]
Mean ( Full Range )
  52.6  
  ( 40 to 65 )  
  57.2  
  ( 41 to 69 )  
  53.8  
  ( 40 to 69 )  
Gender  
[units: Participants]
     
Female     9     3     12  
Male     6     2     8  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Systolic Blood Pressure, Change From Baseline to End of Treatment   [ Time Frame: Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period ]

2.  Primary:   Diastolic Blood Pressure, Change From Baseline to End of Treatment   [ Time Frame: Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period ]

3.  Primary:   Pulse, Change From Baseline to End of Treatment   [ Time Frame: Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period ]

4.  Primary:   Weight, Change From Baseline to End of Treatment   [ Time Frame: Baseline is the day before first dose, end of treatment is last day of treatment ]

5.  Primary:   Clinically Relevant Change of Laboratory Variables   [ Time Frame: Measured regularly from day before first dose to day after last dose ]

6.  Secondary:   Area Under the Plasma Concentration vs Time Curve (AUC0-24) of AZD1656   [ Time Frame: Measured last day of treatment ]

7.  Secondary:   Maximum Plasma Concentration of AZD1656   [ Time Frame: Measured following the morning dose last day of treatment ]

8.  Secondary:   Time to Reach Maximum Plasma Concentration of AZD1656   [ Time Frame: Measured last day of treatment ]

9.  Secondary:   Terminal Elimination Half-life of AZD1656   [ Time Frame: Measured following the evening dose last day of treatment ]

10.  Secondary:   Apparent Oral Clearance of AZD1656   [ Time Frame: Measured last day of treatment ]

11.  Secondary:   P-Glucose (AUC0-24)/24, Change From Baseline to End of Treatment   [ Time Frame: Baseline is the day before first dose, end of treatment is last day of treatment ]

12.  Secondary:   S-Insulin (AUC0-24)/24, Change From Baseline to End of Treatment   [ Time Frame: Baseline is the day before first dose, end of treatment is last day of treatment ]

13.  Secondary:   S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment   [ Time Frame: Baseline is the day before first dose, end of treatment is last day of treatment ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The primary objective of the study was to assess safety and tolerability and hence the study was not sized based on statistical considerations. The most import outcome, "no safety or tolerability concerns were identified", is not a numerical variable


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Gerard Lynch
Organization: AstraZeneca
e-mail: aztrial_results_posting@astrazeneca.com


No publications provided


Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00856908     History of Changes
Other Study ID Numbers: D1020C00020
Study First Received: March 5, 2009
Results First Received: July 24, 2012
Last Updated: November 27, 2012
Health Authority: United States: Food and Drug Administration